Knight Therapeutics Inc., a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally. The companys commercialized products include Impavido, an alkyllysophospholipid analogue drug for the treatment of visceral and cutaneous Leishmaniasis; Movantik for the treatment of opioid induced constipation; AzaSite to treat bacterial conjunctivitis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Flat Tummy Tea, a herbal detox tea; and FOCUSfactor, a dietary supplement. Its products under development comprise Probuphine to treat opioid addiction; NeurAxon family to treat acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; Iluvien to treat diabetic macular edema; and Netildex to treat ocular inflammation. The companys products under development also include ATryn for the prevention of thromboembolic events; 60P family to treat tropical diseases; Advaxis family to treat HPV-associated cancers and other diseases; FLEXISEQ to treat pain and joint stiffness associated with osteoarthritis; Hand MD, a line of anti-aging hand skincare products; and Crescita family, a line of dermo-cosmetic products. In addition, it finances other life science companies; and invests in life sciences venture capital funds. The company is headquartered in Montreal, Canada.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Symbol: CVE:GUD
- CUSIP: N/A
- Web: www.gud-knight.com
- Market Cap: C$1.23 billion
- Outstanding Shares: 142,765,000
- 50 Day Moving Avg: C$8.63
- 200 Day Moving Avg: C$9.77
- 52 Week Range: C$8.25 - C$11.03
Sales & Book Value:
- Trailing P/E Ratio: 60.07
- P/E Growth: 2880.00
- Annual Revenue: C$7.97 million
- Price / Sales: 154.59
- Book Value: C$6.87 per share
- Price / Book: 1.26
- Average Volume: 169,151 shs.
- Short Ratio: 4.2
Frequently Asked Questions for Knight Therapeutics (CVE:GUD)
What is Knight Therapeutics' stock symbol?
Knight Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "GUD."
Who are some of Knight Therapeutics' key competitors?
Some companies that are related to Knight Therapeutics include Indivior PLC (INDV), Hutchison China MediTech Limited (HCM), Abcam Plc (ABC), Udg Healthcare PLC (UDG), Dechra Pharmaceuticals plc (DPH), Biohaven Pharmaceutical Holding Co Ltd (BHVN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Genus plc (GNS), Clinigen Group PLC (CLIN), ProMetic Life Sciences (PLI), Asante Solutions (PUMP), National HealthCare (NHC), Spire Healthcare Group PLC (SPI), Canfor Pulp Products (CFX), Extendicare (EXE), Novadaq Technologies (NDQ) and CVS Group Plc (CVSG).
How do I buy Knight Therapeutics stock?
Shares of Knight Therapeutics and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Knight Therapeutics' stock price today?
MarketBeat Community Rating for Knight Therapeutics (CVE GUD)MarketBeat's community ratings are surveys of what our community members think about Knight Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Knight Therapeutics stock can currently be purchased for approximately C$8.63.
Consensus Ratings for Knight Therapeutics (CVE:GUD) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Knight Therapeutics (CVE:GUD)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Knight Therapeutics (CVE:GUD)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Knight Therapeutics (CVE:GUD)
Current Year EPS Consensus Estimate: $0.10 EPS
Dividend History for Knight Therapeutics (CVE:GUD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Knight Therapeutics (CVE:GUD)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Knight Therapeutics (CVE:GUD)
Latest Headlines for Knight Therapeutics (CVE:GUD)
Knight Therapeutics (GUD) Chart for Friday, September, 22, 2017